Predictors of Cognitive Decline in Normal Aging

Alzheimer Disease Clinical Trial

Official title:

Predictors of Cognitive Decline in Normal Aging

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00094939
• Other study ID #: IA0056
• Secondary ID: R01AG012101
• Status: Recruiting
• Phase: N/A
• First received: October 28, 2004
• Last updated: December 10, 2009
• Start date: September 2003
• Est. completion date: August 2008

Study information

• Verified date: September 2009
• Source: National Institute on Aging (NIA)
• Contact: Kenneth E. Rich
• Phone: 212-263-7563
• Email: kenneth.rich[@]med.nyu.edu
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

The goal of this project is to develop an early diagnostic test for Alzheimer's disease (AD) by monitoring loss of neurons and brain size reductions over a period of five years.

Description:

Studies of normal aging and mild cognitive impairment (MCI) show that loss of neurons and reduction in size of the hippocampal part of the brain predict a person's conversion from MCI to Alzheimer's disease (AD). Increases in tangle-related abnormal tau proteins, specifically P-tau231, also appear to be related.

This study will collect neuropsychological data, magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) from volunteer participants to measure the relationship between changes in brain volume, CSF levels, and memory performance.

From the data researchers hope to develop an early diagnostic test for AD.

The study will include 170 participants between the ages of 60 and 80 years, some normal, some with MCI, some with mild AD, and some with frontotemporal dementia. After initial screening of volunteers, the researchers will give participants a complete baseline exam and 24-month follow-up exams over a period of five years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 170
• Est. completion date: August 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 60 Years to 80 Years

Eligibility

Inclusion Criteria:

• Males and females, from all racial and ethnic categories between the ages of 60-80 years of age, with English as their first language.

• Residents of the New York City metropolitan area.

• Minimum of 12 years of education.

• Participants will be grouped according to the following classifications: normal aging, mild cognitive impairment (MCI), Alzheimer's disease (AD), or frontotemporal dementia (FTD).

• Participants will agree to ApoE genotyping and DNA banking.

Exclusion Criteria:

• Past history or MRI evidence of brain damage including significant trauma, stroke, hydrocephalus, lacunar infarcts, seizures, mental retardation or serious neurological disorder.

• Significant history of alcoholism or drug abuse.

• History of psychiatric illness (e.g., schizophrenia, mania or depression).

• Any focal signs or significant neuropathology.

• A score of 4 or greater on the Modified Hachinski Ischemia Scale suggesting cerebrovascular disease.

• A total score of 16 or more on the Hamilton Depression Scale to exclude possible cases of primary depression.

• Evidence of clinically relevant and uncontrolled hypertensive, cardiac, pulmonary, vascular, metabolic or hematologic conditions.

• Physical impairment of such severity as to adversely affect the validity of psychological testing.

• Hostility or refusal to cooperate.

• Any prosthetic devices (e.g., pacemaker or surgical clips) that could be affected by the magnetic field employed during MRI imaging.

• History of familial early onset dementia.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Alzheimer Disease
• Dementia

Locations

Country	Name	City	State
United States	Center for Brain Health, Silberstein Institute, New York University School of Medicine	New York City	New York

Sponsors (1)

Lead Sponsor	Collaborator
National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann-Kiefer K, McCulloch C, Ptok U, Heun R, Andreasen N, DeBernardis J, Kerkman D, Moeller H, Davies P, Hampel H. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002 Aug 27;59(4):627-9. Erratum in: Neurology. 2004 Sep 28;63(6):1144. — View Citation

de Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, Convit A, Caraos C, Rusinek H, Tsui W, Saint Louis LA, DeBernardis J, Kerkman D, Qadri F, Gary A, Lesbre P, Wisniewski T, Poirier J, Davies P. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett. 2002 Nov 29;333(3):183-6. — View Citation

Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000 Jan;57(1):100-5. — View Citation